February 4, 2022 

SUBJECT: FDA approves the first treatment for patients with Cold Agglutinin Disease (CAD)

• Enjaymo™ (sutimlimab-jome) is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with Cold Agglutinin Disease (CAD)

• Enjaymo™ addresses a serious and chronic unmet medical need for adults living with CAD, a rare blood disorder

The U.S. Food and Drug Administration (FDA) has approved Enjaymo™ to decrease the need for red blood cell transfusion due to hemolysis in adults with CAD. Enjaymo is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells (hemolysis).

Read full article: https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-04-23-00-00-2379517